Clinical Trials on MSI-H Tumors

Total 17547 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H Tumors

United States
BeiGene

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

MSI-H/dMMR Solid Tumor

China
Yonsei University
Merck KGaA, Darmstadt, Germany

Active, not recruiting

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of
Peking University Cancer Hospital & Institute

Recruiting

Registry Study in MSI/dMMR Solid Tumors

Solid Tumor | MSI-H | DMMR Cancer

China
University of Utah
Elevar Therapeutics

Terminated

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE)

Urothelial Carcinoma | Advanced Malignancies | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | MSI-H or dMMR Solid Tumors

United States
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
University Medical Center Groningen

Recruiting

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN)

Melanoma | Head and Neck Neoplasms | MSI-H Cancer

Netherlands
Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
Shen Lin

Not yet recruiting

An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors

To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer

China
Centre Leon Berard
Agenus Inc.

Not yet recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME)

Gastric Cancer | Metastatic Cancer | Advanced Cancer | MSI-H

France
University of Campania "Luigi Vanvitelli"

Completed

Predictive Value of DNA Mismatch Repair System in Colorectal Cancers (DNAMMR)

MSI-H Colorectal Cancer
Fudan University

Not yet recruiting

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Gastric Cancer | MSI-H | Adjuvant Therapy | PD-1 Immunotherapy

China
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Capecitabine | MSI-H Colorectal Cancer | Oxaliplatin | Tislelizumab
Apexigen America, Inc.

Completed

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Melanoma | Cancer | Head and Neck Cancer | NSCLC | Urothelial Carcinoma | MSI-H

United States
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb

Active, not recruiting

Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT)

Neuroendocrine Tumors | Advanced Biliary Tract Cancer | Female Reproductive System Neoplasm | MSI-H Solid Malignant Tumor

New Zealand, Australia
Tianjin Medical University Cancer Institute and...

Recruiting

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

MSI-H Advanced Colorectal Cancer

China
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Sun Yat-sen University

Active, not recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
Sun Yat-sen University

Recruiting

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III | MSI-H | Mmr Deficiency

China
Akdeniz University
The Scientific and Technological Research Council of Turkey

Completed

The Effect of an Avatar-Based Education Program on Shunt Complications and Parents' Knowledge and Care Skills

Developing the ABEP-H | Determining the Effect of ABEP-H

Turkey
OneBlood, Inc.
OrSense, Ltd.

Completed

NBM-200 Clinical Study in Blood Donation Setting

Hemoglobin H

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
Ramathibodi Hospital

Completed

Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori

H Pylori Eradication

Thailand
University of Zurich

Terminated

PET/MRI Perfusion and CT Perfusion in Solid Tumors (Perfusion)

CT Perfusion and MRI Perfusion in Solid Tumors

Switzerland
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Peking University

Not yet recruiting

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
University of Latvia
National Institute of Public Health, Slovenia; Iuliu Hatieganu University of... and other collaborators

Recruiting

H. Pylori Screen-and-treat Study in a Population of Young Adults

Gastric Cancer | H Pylori Infection | H Pylori Eradication | H-pylori

Poland, Croatia, Ireland, Latvia, Romania, Slovenia
Assistance Publique - Hôpitaux de Paris

Unknown

Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection (Hepysé)

H Pylori Eradication | H Pylori Infection Eradication | Antibiotics Therapeutic Strategies

France
Zhejiang University

Recruiting

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

MSS | Locally Advanced Rectal Carcinoma | pMMR | MSI-L

China
University Hospital, Clermont-Ferrand
Hospices Civils de Lyon; Centre Hospitalier Universitaire de Saint Etienne; University... and other collaborators

Completed

Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy (WIN IN WEAN)

Adult Patients Ventilated More Than 48 h

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

MSI Positive Colorectal Cancer | MSI Negative Colorectal Cancer | MSI Positive Non-Colorectal Cancers

United States
Universitaire Ziekenhuizen KU Leuven

Unknown

Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors (s51240)

Non-invasive | Gastro-intestinal Tumor | Accurate Staging | Whole-body Diffusion Weighted MRI

Belgium
Soonchunhyang University Hospital

Completed

Bismuth for PCAB-based H. Pylori Eradication

H. Pylori Infection

Korea, Republic of
ARJ Medical, Inc.

Completed

ARJ C13 Urea Breath Test System

H. Pylori Infection

United States
Hamamatsu University

Unknown

Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori (EHR)

H. Pylori Infection

Japan
National Taiwan University Hospital

Completed

Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori

H. Pylori Infection

Taiwan
National Cancer Institute (NCI)

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor

United States

Clinical Trials on MSI-H Tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations